{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:44:42Z","timestamp":1757587482476},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":10427,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1978,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The case history of a child with acute promyelocytic leukemia (APL) is reported to illustrate both an unusual presentation of APL as a pelvic mass and to review the pathophysiology and treatment of the disease. Therapy of APL consists of chemotherapy, namely adriamycin\/daunomycin for remission induction, and of control of disseminated intravascular coagulation. A chloroma, if present, may require local irradiation in addition to chemotherapy. With aggressive management, the number of prolonged remissions may be greater for APL than for any other form of acute myelogenous leukemia (AML), with significant numbers of patients achieving five\u2010year survival.<\/jats:p>","DOI":"10.1002\/mpo.2950040403","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T14:58:34Z","timestamp":1171983514000},"page":"289-295","source":"Crossref","is-referenced-by-count":19,"title":["Acute promyelocytic leukemia presenting as a pelvic mass"],"prefix":"10.1002","volume":"4","author":[{"given":"Jean Bello","family":"Belasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Hugh","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Campbell W.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"417","article-title":"Les aspects du syndrome h\u00e9morragique des leuc\u00e9mies","volume":"20","author":"Croizat P","year":"1949","journal-title":"Le Sang"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1957.tb00124.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V23.6.717.717","article-title":"Acute promyelocytic leukemia with fibrinogen and factor V deficiencies","volume":"23","author":"Didisheim P","year":"1964","journal-title":"Blood"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V21.4.495.495","article-title":"Acute promyelocytic leukemia associated with hypofibrinogenemia","volume":"21","author":"Rosenthal RL","year":"1963","journal-title":"Blood"},{"key":"e_1_2_1_6_2","first-page":"755","article-title":"A propos de la leuc\u00e9mie \u00e0 promyelocytes","volume":"13","author":"Bernard J","year":"1973","journal-title":"Nouv Rev Franc d'Hematol"},{"key":"e_1_2_1_7_2","first-page":"604","article-title":"La leucose aigu\u00eb \u00e0 promy\u00e9locytes. Etude portant sur vingt observations","volume":"23","author":"Bernard J","year":"1959","journal-title":"Schw Med Wochenschr"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","article-title":"Acute promyelocytic leukemia. Results of treatment by daunorubicin","volume":"41","author":"Bernard J","year":"1973","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.136.12.1389"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1973.tb05730.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(72)90066-6"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb01834.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(74)80037-7"},{"key":"e_1_2_1_14_2","first-page":"334","article-title":"Acute promyelocytic leukemia","volume":"7","author":"Armitage JO","year":"1975","journal-title":"Rock Mountain Med J"},{"key":"e_1_2_1_15_2","first-page":"761","article-title":"Traitement dans 18 observations de leuc\u00e9mies aigu\u00ebs promy\u00e9locytaires de la coagulation intravasculaire diss\u00e9min\u00e9","volume":"13","author":"Dreyfus B","year":"1973","journal-title":"Nouv Rev Franc d'Hematol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(72)80004-3"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1973.tb00125.x"},{"key":"e_1_2_1_18_2","first-page":"115","article-title":"Role of chemical structure in biochemical activity of daunorubicin, adriamycin, and some structural analogs: Macromolecular interactions and their biological consequences","volume":"6","author":"Chandra P","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_19_2","first-page":"107","article-title":"Cell interactions: Determinants of selective toxicity of adriamycin and daunorubicin","volume":"6","author":"Schwartz HS","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950010107"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197307)32:1<253::AID-CNCR2820320137>3.0.CO;2-W"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1964.02090010064008"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood.V42.5.721.721","article-title":"Chloroma and other myeloblastic tumors","volume":"42","author":"Muss HB","year":"1973","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1961.03620120048008"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197604)37:4<1808::AID-CNCR2820370427>3.0.CO;2-U"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V35.3.361.361","article-title":"Granulocytic sarcoma (chloroma)","volume":"35","author":"Wiernik P","year":"1970","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0021-9258(18)69839-4","article-title":"Iron (II) inactivation of myeloperoxidase","volume":"234","author":"Schultz J","year":"1959","journal-title":"J Biol Chem"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950040403","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950040403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T22:06:07Z","timestamp":1699826767000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950040403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1978,1]]}},"alternative-id":["10.1002\/mpo.2950040403"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950040403","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1978,1]]}}}